Literature DB >> 22767366

Cardiac involvement in Anderson-Fabry disease.

Filippo Maria Cauti1, Constantinos O'Mahony, Antonis Pantazis.   

Abstract

A normotensive 50-year-old man was evaluated for cardiac symptoms associated with left ventricular hypertrophy (LFH). His symptoms were caused by cardiac involvement from Anderson-Fabry disease (AFD), an X linked lysosomal storage disease caused by mutations in the GLA gene which encodes for the lysosomal enzyme -galactosidase A. He was treated with recombinant enzyme but the clinical course was complicated by arrhythmias and the patient required an internal cardioverter defibrillator. Even though AFD is rare, this case illustrates the importance of considering the diagnosis in selected patients as effective treatment has recently become available. Recognition of AFD also allows for screening of asymptomatic relatives who may benefit from treatment before irreversible life-threatening complications develop.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22767366      PMCID: PMC3029827          DOI: 10.1136/bcr.02.2010.2760

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  10 in total

1.  Prevalence and clinical significance of cardiac arrhythmia in Anderson-Fabry disease.

Authors:  Jaymin S Shah; Derralynn A Hughes; Bhavesh Sachdev; Maite Tome; Deirdre Ward; Philip Lee; Atul B Mehta; Perry M Elliott
Journal:  Am J Cardiol       Date:  2005-09-15       Impact factor: 2.778

2.  An atypical variant of Fabry's disease in men with left ventricular hypertrophy.

Authors:  S Nakao; T Takenaka; M Maeda; C Kodama; A Tanaka; M Tahara; A Yoshida; M Kuriyama; H Hayashibe; H Sakuraba
Journal:  N Engl J Med       Date:  1995-08-03       Impact factor: 91.245

3.  Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey.

Authors:  Ales Linhart; Christoph Kampmann; José L Zamorano; Gere Sunder-Plassmann; Michael Beck; Atul Mehta; Perry M Elliott
Journal:  Eur Heart J       Date:  2007-05-05       Impact factor: 29.983

4.  Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases.

Authors:  Perry Elliott; Bert Andersson; Eloisa Arbustini; Zofia Bilinska; Franco Cecchi; Philippe Charron; Olivier Dubourg; Uwe Kühl; Bernhard Maisch; William J McKenna; Lorenzo Monserrat; Sabine Pankuweit; Claudio Rapezzi; Petar Seferovic; Luigi Tavazzi; Andre Keren
Journal:  Eur Heart J       Date:  2007-10-04       Impact factor: 29.983

Review 5.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

Review 6.  The cerebral vasculopathy of Fabry disease.

Authors:  David F Moore; Christine R Kaneski; Hasan Askari; Raphael Schiffmann
Journal:  J Neurol Sci       Date:  2007-03-23       Impact factor: 3.181

7.  Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey.

Authors:  A Mehta; R Ricci; U Widmer; F Dehout; A Garcia de Lorenzo; C Kampmann; A Linhart; G Sunder-Plassmann; M Ries; M Beck
Journal:  Eur J Clin Invest       Date:  2004-03       Impact factor: 4.686

8.  Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment.

Authors:  Frank Weidemann; Markus Niemann; Frank Breunig; Sebastian Herrmann; Meinrad Beer; Stefan Störk; Wolfram Voelker; Georg Ertl; Christoph Wanner; Jörg Strotmann
Journal:  Circulation       Date:  2009-01-19       Impact factor: 29.690

Review 9.  Update on Fabry disease: kidney involvement, renal progression and enzyme replacement therapy.

Authors:  Frank Breunig; Christoph Wanner
Journal:  J Nephrol       Date:  2008 Jan-Feb       Impact factor: 3.902

Review 10.  Anderson-Fabry disease and the heart.

Authors:  Constantinos O'Mahony; Perry Elliott
Journal:  Prog Cardiovasc Dis       Date:  2010 Jan-Feb       Impact factor: 8.194

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.